Huihe Biotechnology

Huihe Biopharma is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, dedicated to the development of novel multi-specific antibodies for oncology and autoimmune diseases. The company utilizes its proprietary Tri-specific T-cell Engager (TriTE) platform to engineer therapies that simultaneously target multiple tumor antigens and activate T-cells for precise cancer cell eradication. Its lead candidate, HHB-3002, is a first-in-class trispecific antibody targeting CD3, CD19, and CD20, currently undergoing Phase 1 clinical evaluation for B-cell malignancies. Beyond its lead program, Huihe is advancing a pipeline of trispecific engagers for multiple myeloma and other hematologic cancers. The company is led by a team of industry experts with significant experience in antibody drug discovery and global clinical development. Huihe Biopharma has successfully secured multiple rounds of venture capital funding to support its transition into a fully integrated biotechnology enterprise.